These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35029046)

  • 1. "LONG COVID"-A hypothesis for understanding the biological basis and pharmacological treatment strategy.
    Jarrott B; Head R; Pringle KG; Lumbers ER; Martin JH
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00911. PubMed ID: 35029046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics.
    Choi HM; Moon SY; Yang HI; Kim KS
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
    Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
    Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Tropism in the Lungs, Airways, and Vascular Endothelium of Patients With Fatal Coronavirus Disease 2019: An Autopsy Case Series.
    Bhatnagar J; Gary J; Reagan-Steiner S; Estetter LB; Tong S; Tao Y; Denison AM; Lee E; DeLeon-Carnes M; Li Y; Uehara A; Paden CR; Leitgeb B; Uyeki TM; Martines RB; Ritter JM; Paddock CD; Shieh WJ; Zaki SR
    J Infect Dis; 2021 Mar; 223(5):752-764. PubMed ID: 33502471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation.
    Østergaard L
    Physiol Rep; 2021 Feb; 9(3):e14726. PubMed ID: 33523608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
    LaVergne SM; Stromberg S; Baxter BA; Webb TL; Dutt TS; Berry K; Tipton M; Haberman J; Massey BR; McFann K; Alnachoukati O; Zier L; Heacock T; Ebel GD; Henao-Tamayo M; Dunn J; Ryan EP
    BMC Infect Dis; 2021 Jul; 21(1):677. PubMed ID: 34256735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent SARS-2 infections contribute to long COVID-19.
    Jacobs JJL
    Med Hypotheses; 2021 Apr; 149():110538. PubMed ID: 33621843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible Application of Melatonin in Long COVID.
    Cardinali DP; Brown GM; Pandi-Perumal SR
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision therapeutic targets for COVID-19.
    Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
    Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce 'Brain Fog' and Results in Behavioral Changes that Favor Viral Survival.
    Stefano GB; Ptacek R; Ptackova H; Martin A; Kream RM
    Med Sci Monit; 2021 Jan; 27():e930886. PubMed ID: 33487628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort.
    Caspersen IH; Magnus P; Trogstad L
    Eur J Epidemiol; 2022 May; 37(5):539-548. PubMed ID: 35211871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.
    Higashikuni Y; Liu W; Obana T; Sata M
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 long haulers.
    Schmidt C
    Nat Biotechnol; 2021 Aug; 39(8):908-913. PubMed ID: 34257426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic Changes of the Blood Chemistry in Syrian Hamsters Post-Acute COVID-19.
    Hsu CJ; Lin WC; Chou YC; Yang CM; Wu HL; Cheng YH; Liu PC; Chang JY; Chen HY; Sun JR
    Microbiol Spectr; 2022 Feb; 10(1):e0236221. PubMed ID: 35196799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.